Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Semin Thromb Hemost 2005; 31(1): 25-32
DOI: 10.1055/s-2005-863802
DOI: 10.1055/s-2005-863802
A Review of the Clinical and Diagnostic Utility of Laboratory Tests for the Detection of Congenital Thrombophilia
Further Information
Publication History
Publication Date:
11 February 2005 (online)
![](https://www.thieme-connect.de/media/sth/200501/lookinside/thumbnails/10.1055-s-2005-863802-1.jpg)
ABSTRACT
Laboratory tests to detect congenital thrombophilia are frequently requested by clinicians. This review attempts to define (1) whether and to what extent laboratory testing may help clinicians make decisions on patient management, (2) the types of conditions to be investigated, and (3) the types of testing to be performed for each condition.
KEYWORDS
Thrombophilia - screening - thrombosis - laboratory testing
REFERENCES
- 1 Greaves M, Baglin T. Laboratory testing for heritable thrombophilia: impact on clinical management of thrombotic disease. Br J Haematol. 2000; 109 699-703
- 2 Mannucci P M. Genetic hypercoagulability: prevention suggests testing family members. Blood. 2001; 98 21-22
- 3 De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood. 1996; 87 3531-3544
- 4 Eichinger S, Pabinger I, Stumpflen A et al.. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost. 1997; 77 624-628
- 5 Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of anticoagulation. Thromb Haemost. 1999; 81 684-689
- 6 Kearon C, Gent M, Hirsh J et al.. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999; 340 901-907
- 7 Eichinger S, Weltermann A, Mannhalter C et al.. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med. 2002; 162 2357-2360
- 8 Ridker P M, Miletich J P, Stampfer M J, Goldhaber S Z, Lindpaintner K, Hennekens C H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995; 92 2800-2802
- 9 Simioni P, Prandoni P, Lensing A W et al.. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997; 336 399-403
- 10 Simioni P, Prandoni P, Lensing A W et al.. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000; 96 3329-3333
- 11 Eichinger S, Minar E, Hirschl M et al.. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999; 81 14-17
- 12 Miles J S, Miletich J P, Goldhaber S Z, Hennekens C H, Ridker P M. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001; 37 215-218
- 13 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995; 85 1504-1508
- 14 Koeleman B PC, Reitsma P H, Allaart C F, Bertina R M. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood. 1994; 84 1031-1035
- 15 Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995; 85 3518-3523
- 16 Van Boven H H, Reitsma P H, Rosendaal F R et al.. Factor V Leiden (FVR506Q) in families with inherited antithrombin deficiency. Thromb Haemost. 1996; 75 417-421
- 17 Ridker P M, Hennekens C H, Selhub J, Miletich J P, Malinow M R, Stampfer M J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and the risk of future venous thromboembolism. Circulation. 1997; 95 1777-1782
- 18 Lane D A, Bayston T, Olds R J et al.. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997; 77 197-211
- 19 Demers C, Henderson P, Blajchman M A et al.. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost. 1993; 69 231-235
- 20 Ungerstedt J S, Schulman S, Egberg N, Antovic J, Blombäck M. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?. Blood. 2002; 99 2271-2272
- 21 Perry D J, Daly M E, Tait R C et al.. Antithrombin Cambridge II (Ala384Ser): clinical, functional and haplotype analysis of 18 families. Thromb Haemost. 1998; 79 249-253
- 22 Sas G, Pepper D S. Detection of thrombin-antithrombin III complex by crossed immunoelectrophoresis. Thromb Res. 1976; 9 95-97
- 23 Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost. 1987; 58 1094
- 24 Reitsma P H, Bernardi F, Doig R G et al.. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995; 73 876-889
- 25 De Moerloose P, Reber G, Bouviar C A. Spuriously low levels of protein C with Protac activation clotting assay. Thromb Haemost. 1988; 59 543
- 26 Simioni P, Lazzaro A, Zanardi S, Girolami A. Spurious protein C deficiency due to antiphospholipid antibodies. Am J Hematol. 1991; 36 299-301
- 27 Faioni E M, Franchi F, Asti A, Mannucci P M. Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach. Blood Coagul Fibrinolysis. 1996; 7 349-352
- 28 Faioni E M, Hermida J, Rovida E et al.. Type II protein C deficiency: identification and molecular modeling of two natural mutants with low anticoagulant and normal amydolitic activity. Br J Haematol. 2000; 108 265-271
- 29 Bovill E G, Tomczak J A, Grant B et al.. Protein CVermont: symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood. 1992; 79 1456-1465
- 30 Gandrille S, Borgel D, Sala N et al.. Plasma Coagulation Inhibitors. Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Protein S deficiency: a database of mutations-summary of the first update. Thromb Haemost. 2000; 84 918
- 31 Preda L, Tripodi A, Valsecchi C, Lombardi A, Finotto E, Mannucci P M. A prothrombin time-based functional assay of protein S. Thromb Res. 1990; 60 19-32
- 32 Wolf M, Boyer-Neumann C, Martinoli J L et al.. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost. 1989; 62 1144-1145
- 33 Faioni E M, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci P M. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost. 1993; 70 1067-1071
- 34 Faioni E M, Boyer-Neumann C, Franchi F, Wolf M, Meyer D, Mannucci P M. Another protein S functional assay is sensitive to resistance to activated protein C. Thromb Haemost. 1994; 72 648
- 35 Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin-K dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 1988; 68 437-443
- 36 Amiral J, Grosley B, Boyer-Neuman C et al.. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coagul Fibrinolysis. 1994; 5 179-186
- 37 Giri T K, Hillarp A, Hardig Y, Zoller B, Dahlbäck B. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost. 1998; 79 767-772
- 38 Simmonds R E, Ireland H, Lane D A, Zoller B, Garcia de Frutos P, Dahlbäck B. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med. 1998; 128 8-14
- 39 Makris M, Leach M, Beauchamp N J et al.. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood. 2000; 95 1935-1941
- 40 Dahlbäck B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993; 90 1004-1008
- 41 Exner T, Murray B, Chong B H, Chesterman C N. Improved APC resistance method based on a Russell's Viper Venom clotting test. Thromb Haemost. 1995; 73 1119
- 42 Le D T, Greegard J S, Mujumdar V, Rapaport S I. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood. 1995; 85 1704-1711
- 43 Alhenc-Gelas M, Aillaud M F, Bonvarlet M N, Dupuy G, Juhan-Vague I, Aiach M. Specificity of an assay based on a factor V-depleted plasma in patients carrying the Arg 506 Gln mutation. Thromb Haemost. 1996; 75 971-977
- 44 Hoagland L E, Triplett D A, Peng F, Barna L. APC-resistance as measured by a textarin time assay: comparison to the APTT-based method. Thromb Res. 1996; 83 363-373
- 45 Bertina R M, Koeleman B P, Koster T et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369 64-67
- 46 Bernardi F, Faioni E M, Castoldi E et al.. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997; 90 1552-1557
- 47 Williamsson D, Brown K, Luddington R, Baglin C, Baglin T. A new mutation (Arg306Thr) associated with resistance to activated protein C. Blood. 1998; 91 1140-1144
- 48 Varadi K, Moritz B, Lang H et al.. A chromogenic assay for activated protein C resistance. Br J Haematol. 1995; 90 884-889
- 49 Rosing J, Tans G, Nicolaes G A et al.. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997; 97 233-238
- 50 de Ronde H, Bertina R M. Laboratory diagnosis of APC resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost. 1994; 72 880-886
- 51 Halbmayer D M, Hanshofer A, Schon R, Fisher M. Influence of lupus anticoagulant on a commercially available kit for APC-resistance. Thromb Haemost. 1994; 72 645-646
- 52 Tripodi A, Negri B, Bertina R M, Mannucci P M. Screening of the FV:Q506 mutation. Evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost. 1997; 77 436-439
- 53 Simioni P, Scudeller A, Radossi P et al.. “Pseudo homozygous” activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost. 1996; 75 422-426
- 54 Jorquera J I, Montoro J M, Angeles Fernandez M, Aznar J A, Aznar J. Modified test for activated protein C resistance. Lancet. 1994; 344 1162-1163
- 55 Kraus M, Noah M, Fickensher K. The PCAT. A simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res. 1995; 79 217-222
- 56 Preda L, Simioni P, Legnani C et al.. A new global test for the evaluation of the protein C-protein S system. Blood Coagul Fibrinolysis. 1996; 7 465-469
- 57 Robert A, Eschwege V, Hameg H, Drouet L, Aillaud M F. Anticoagulant response to Agkistrodon contortrix venom (ACV test): a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost. 1996; 75 562-566
- 58 Gable P S, Le D T, McGehe W, Rapaport S I. A Protac-based screening test for activated protein-resistance factor Va and other defects of the protein C anticoagulant pathway. Blood Coagul Fibrinolysis. 1997; 8 327-335
- 59 Rylatt D B, Hohnen-Behrens C, Pilgrim R L, Dickeson L E, Neal M, Exner T. Detecting APC resistant factor V: a functional method without plasma dilutions. Blood Coagul Fibrinolysis. 1999; 10 359-366
- 60 Tripodi A, Akhavan S, Asti D, Faioni E M, Mannucci P M. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway. Blood Coagul Fibrinolysis. 1998; 9 485-489
- 61 Denson K WE, Haddon M E, Reed S V, Davidson S, Littlewood T J. A more discriminating test for APC resistance and possible screening test to include protein C and protein S. Thromb Res. 1996; 81 151-156
- 62 Sidelmann J, Gram J, Dyg Pedersen O, Jespersen J. Influence of plasma platelets on activated protein C resistance assay. Thromb Haemost. 1995; 74 993-994
- 63 Tripodi A, Valsecchi C, Chantarangkul V, Battaglioli T, Mannucci P M. Standardisation of activated protein C resistance testing. Effect of residual platelets in frozen plasmas assessed with commercial and home made methods. Br J Haematol. 2003; 120 825-828
- 64 Tripodi A, Chantarangkul V, Negri B, Mannucci P M. Standardization of the APC-resistance test. Effects of normalization of results by means of pooled normal plasma. Thromb Haemost. 1998; 79 564-566
- 65 Rosen S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasma from healthy individuals. Thromb Haemost. 1994; 72 255-260
- 66 Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci P M. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations. A cause for concern. Thromb Haemost. 2002; 88 690-691
- 67 de Visser M CH, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999; 93 1271-1276
- 68 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999; 130 643-650
- 69 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood. 1996; 88 3698-3703
- 70 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995; 73 151-161
- 71 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999; 81 165-176
- 72 Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci P M, Cattaneo M. Multicenter study of homocysteine measurement. Performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost. 2001; 85 291-295
- 73 Bauer K A. Conventional fibrinolytic assays for the evaluation of patients with venous thrombosis: don't bother. Thromb Haemost. 2001; 85 377-378
- 74 Ariens R A, Alberio G, Moia M, Mannucci P M. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost. 1999; 81 203-207
Dr.
A. Tripodi
Via Pace 9, 20122 Milano, Italy
Email: armando.tripodi@unimi.it